Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value [Seeking Alpha]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Seeking Alpha
Myriam Alvarez 1.43K Follower s Follow Summary Ionis Pharmaceuticals specializes in RNA-targeted therapies for neurological and cardiometabolic diseases using antisense DNA technology. The company has a robust pipeline with over 40 drug candidates, developed in partnership with major pharmaceutical companies and in-house. In 2024, Ionis launched Wainua for ATTRv-PN and Qalsody for SOD1-ALS, marking significant milestones in its product portfolio. I believe IONS is a solid long-term bet despite trading at a slight premium relative to peers. kemalbas Ionis Pharmaceuticals, Inc. ( NASDAQ: IONS ) is a biopharmaceutical company specializing in RNA-targeted therapies. It uses antisense DNA technology to design drugs that regulate the production of specific proteins to treat neurological and cardiometabolic diseases, directly addressing their root causes. The company presents an Recommended For You About IONS Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis announces pricing of $500.3 million public offeringPR Newswire
- Ionis announces proposed public offering of common stockPR Newswire
- Ionis to present at upcoming investor conferencesPR Newswire
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at JPMorgan Chase & Co. from $50.00 to $55.00. They now have a "neutral" rating on the stock.MarketBeat
- Positive Clinical Observations from n-Lorem Treated, KIF1A Nano-rare Patient Published in Nature Medicine [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 8/1/24 - Beat
IONS
Sec Filings
- 9/12/24 - Form 8-K
- 9/10/24 - Form 424B5
- 9/9/24 - Form 8-K
- IONS's page on the SEC website